Biomedical industry should build technical barriers into moats

According to the data from the National Bureau of statistics, in the first half of 2017, China's pharmaceutical manufacturing industry achieved an operating revenue of 1463.67 billion yuan, an increase of 12.6% year on year; and a total profit of 159.63 billion yuan, an increase of 15.9% year on year Wu Zhen, deputy director of the State Food and drug administration, said at the opening ceremony of the 2017 Seminar on drug quality management in developing countries that after years of development, China has become the world's second largest pharmaceutical consumer market and big API exporter (biomedical industry should build technical barriers into moats photo source: Baidu photo) behind the profit growth of the pharmaceutical industry is China's economic development, the improvement of people's healthy living standards, the expansion of demand for medical supplies, and the promotion of frequent policies to support the pharmaceutical manufacturing industry It can be seen that the domestic pharmaceutical industry is ushering in a good opportunity for development, especially in the field of biomedicine New drug research and development has a "double ten" law, that is, the research and development of a drug will take ten years, billion dollars Due to the long R & D cycle, high R & D cost, high risk and technical barriers, sufficient time, technology and financial support are needed Experts said that the pharmaceutical industry is a new industry with intensive knowledge, high technology content, multi-disciplinary and high integration and mutual penetration In particular, China's biopharmaceutical technology research started late, the overall foundation is relatively weak, the level of biopharmaceutical industrialization is very low, and the gap is obvious compared with Europe, the United States, Japan and other countries In order to encourage the development of domestic Biopharmaceutical Enterprises, the state has issued a series of supporting policies It is reported that in the second half of this year, China will introduce the 13th five year plan for biomedicine According to the plan, during the 13th Five Year Plan period, China's biomedical industry will focus on the development of several innovative drug categories, such as chemical drugs for major diseases, biotechnology drugs, new vaccines, new cell therapy preparations, and other major medical technologies, such as bio 3D printing technology In addition to the deployment of drug R & D and technology development, the 13th five year plan of biomedicine also puts forward new development goals for the whole industry, which will further promote the international development of the whole industry We will promote China's Biopharmaceutical Enterprises to meet international standards and systems for drug quality, and help them to enter the international market more quickly Industry insiders pointed out that with the gradual release of relevant system dividends in the second half of the year, the approval of new drugs is expected to be significantly accelerated, and biomedical enterprises will usher in a new round of development opportunities It is estimated that the market scale of China's biopharmaceutical industry will reach 33.3 billion yuan in 2020 With the development of biomedical industry, relevant pharmaceutical technology and pharmaceutical equipment will also be highly valued At present, there are many pharmaceutical process enterprises with long-term vision and related biopharmaceutical equipment enterprises in our country have begun to take the lead in layout For example, in order to achieve aseptic and pollution-free conditions in pharmaceutical workshops, many pharmaceutical enterprises in China strictly follow GMP standards, follow the concept of environmental protection, and replace traditional processes with new biopharmaceutical systems to avoid cross contamination The relevant pharmaceutical equipment, such as biological refrigeration cabinet, biosafety cabinet, biological clean table, biological tank, sterilization equipment, filter, etc., must conform to the new GMP standard and environmental protection concept, so as to ensure the safety of pharmaceutical environment and process without pollution In this regard, many pharmaceutical enterprises further improve the safety and environmental protection production capacity of the equipment from the perspective of environmental protection The author believes that in the second half of the year, the biopharmaceutical industry has ushered in favorable policies, and some production enterprises have been "ready to develop", which also draws the relevant industries eager to try However, the problem of technical barriers in China is a major problem While seizing the opportunity, the relevant equipment R & D and production enterprises must improve the pharmaceutical technology level and the performance of pharmaceutical equipment, rather than just focusing on the production and hard manufacturing, or introducing foreign advanced technology and equipment at a high price They should improve their ability of independent innovation, build the technical barriers into a "moat" to help China's biopharmaceutical industry enter and develop The fast lane of the exhibition.